A Phase 3 clinical trial involving insulin glargine began recruiting as of August 27, 2026. The study, registered as NCT07076199, is titled "A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes."
The trial is designed to compare weekly insulin icodec to daily insulin glargine, with both regimens administered alongside insulin aspart, in adults with type 1 diabetes. According to the registry listing, the study status is currently RECRUITING and the trial is classified as Phase 3.
No outcome data, efficacy results, or safety findings have been reported for this trial at this stage. The listing reflects only the trial's design, comparator, patient population, and current recruitment status as of the date noted.
Readers interested in this trial can find further details through the official clinical trial registry listing. For background on insulin glargine, including its approved uses and general information, see the compound overview.